Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Durvalumab Before and After Operation or Durvalumab as Maintenance Therapy After Chemoradiotherapy Against Superior Sulcus Non-small Cell Lung Cancer

NCT04465968 is registered in ClinicalTrials.gov with National Cancer Center Hospital East as lead sponsor.

NCT NCT04465968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04465968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Durvalumab Before and After Operation or Durvalumab as Maintenance Therapy After Chemoradiotherapy Against Superior Sulcus Non-small Cell Lung Cancer
Lead sponsor
National Cancer Center Hospital East
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 1, 2020
Completion date
August 31, 2030
Enrollment
84 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer stage iii, non-small cell lung cancer stage iib, superior sulcus tumor